Skip Page Header

Home > Amphetamines for Attention Deficit Hyperactivity Disorder (ADHD) in adults.

Castells, Xavier and Ramos-Quiroga, Josep Antoni and Bosch, Rosa and Nogueira, Mariana and Casas, Miguel [The Cochrane Library] . (2011) Amphetamines for Attention Deficit Hyperactivity Disorder (ADHD) in adults. London: John Wiley & Sons, Ltd. Cochrane Database of Systematic Reviews, 6 DOI: 10.1002/14651858.CD007813

URL: http://onlinelibrary.wiley.com/o/cochrane/clsysrev...

Attention Deficit Hyperactivity Disorder (ADHD) is a childhood onset psychiatric disorder that can persist into adulthood in up to 50% of patients. From a clinical point of view, ADHD is characterized by hyperactivity, mood instability, irritability, difficulties in maintaining attention, lack of organization and impulsive behaviours. The presence of other disorders occurring at the the same time is also common, especially mood disorders and substance abuse. It seems that amphetamines could reverse the underlying neurological problems that feature in ADHD, and so improve ADHD symptoms.

We found seven studies, which enrolled 1091 patients. These studies compared amphetamines to placebo and three of them also compared amphetamines with other drugs: guanfacine, modafinil and paroxetine. Three amphetamine derivatives were investigated: dexamphetamine, lisdexamphetamine and mixed amphetamine salts (MAS). Treatment length ranged from two to 20 weeks.

All amphetamines improved ADHD symptoms but overall they did not make people more likely to stay in treatment and were associated with a higher risk of treatment ending early due to adverse events. One type of amphetamine, mixed amphetamine salts, did, however, increase retention in treatment. We found no evidence that higher doses worked better than lower ones. We did not find any difference in effectiveness between immediate-release and sustained-release formulations. Therefore, it appears that short-term treatment with amphetamines reduces ADHD symptoms, but studies assessing the effects of amphetamines for longer periods of time are needed.


Item Type
Evidence resource
Publication Type
Review
Drug Type
CNS stimulants
Intervention Type
AOD disorder drug therapy
Date
2011
Publisher
John Wiley & Sons, Ltd
Place of Publication
London
Volume
6
EndNote
Accession Number
HRB (Not in collection)

Repository Staff Only: item control page